Fundraising FoxAlexandria — 2020 Investments
7 investments dated 2020 · listed companies and verified rows first · show all
Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.
BiotechHealthtechCambridge, US
Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)inJean-François Formela(Director)inOmmer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)inRam Aiyar(Chief Executive Officer, President and Director)inTodd Chappell(Chief Operating Officer)in
Co-investorsAtlas VentureMC Healthcare VenturesNew Enterprise Associates (NEA)Qiming Venture PartnersQiming Venture Partners USARock Springs Capital+3 more
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Founder)
BoardIvan Trifunovich(Director)John Wesley(Founder)
Co-investors8VCAisling CapitalHBM Healthcare InvestmentsHBM PartnersJacket River Capital PartnersMission Bay Capital+5 more
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Daniel Olive(Founder)
Co-investorsAgent CapitalAndera PartnersKurma PartnersPfizer Venture InvestmentsPureos BioventuresBpifrance+4 more
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.
AI & Machine LearningBiotechSouth San Francisco, US
Daphne Koller(Founder)inDuane Valz(General Counsel)inMary Rozenman(Chief Financial Officer)in
BoardRobert Nelsen(Director)Vijay Pande(Director)in
Co-investorsAndreessen HorowitzARCH Venture PartnersDeviation CapitalForesite CapitalGV (Google Ventures)HOF Capital+9 more
Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification.
BiotechDeep TechNew MaterialsSan Diego, US
J. William Efcavitch, Ph.D.(Treasurer and Chief Scientific Officer)Michael J. Kamdar(President, Chief Executive Officer and Secretary)Bill Efcavitch(Founder)Curt Becker(Founder)
BoardDavid Hwang(Director)Larry Stambaugh(Chairman of the Board of Directors)
Co-investors11.2 CapitalDCVC (Data Collective)iSelect FundKeshif VenturesRising TideArgonautic Ventures+2 more
South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.
Daly City, US
Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)
BoardElizabeth Stanley(Director)
Co-investorsAlta PartnersCerity Partners VenturesColorcon Ventures5AM VenturesDCVC (Data Collective)DCVC Bio+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.